Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
Spyre Therapeutics (SYRE) Stock Price & Analysis
394 Followers
SYRE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.66 - $47.97
Previous Close$35.58
Volume12.45K
Average Volume (3M)501.27K
Market Cap
$1.23B
Enterprise Value$946.97M
Total Cash (Recent Filing)$339.28M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.5
Beta0.97
Next Earnings
May 09, 2024EPS Estimate
-$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-75.06
Shares Outstanding36,150,941
10 Day Avg. Volume304,644
30 Day Avg. Volume501,267
Standard Deviation0.42
R-Squared0.13
Alpha-0.00331
Financial Highlights & Ratios
Price to Book (P/B)-1361.51
Price to Sales (P/S)1451.75
Price to Cash Flow (P/CF)-10.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.07K
Enterprise Value/Gross Profit1.07K
Enterprise Value/Ebitda-3.18
Forecast
1Y Price Target
$44.20Price Target Upside29.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Spyre Therapeutics News
PremiumCompany Announcements
Spyre Therapeutics Secures $180M in Strategic Financial Move
Ownership Overview
19.89% Insiders
8.14% Mutual Funds
1.92% Other Institutional Investors
70.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $2.66 and its highest was $47.97 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Currently, no data Available
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Feb 29, 2024. The company reported -$4.05 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$3.323.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -$1.03.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 36,150,940 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$4.05 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went up 8.965%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Among the largest hedge funds holding Spyre Therapeutics’s share is Perceptive Advisors LLC. It holds Spyre Therapeutics’s shares valued at 56M.
---
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.20 (29.66% Upside)
$44.20 (29.66% Upside)
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.8%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
791.16%
12-Months-Change
Fundamentals
Return on Equity
-289.17%
Trailing 12-Months
Asset Growth
380.52%
Trailing 12-Months
Company Description
Spyre Therapeutics
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
---
SYRE Stock 12 Months Forecast
Average Price Target
$44.20
▲(29.66% Upside)
Technical Analysis
Best Analysts Covering SYRE
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+115.80%
reiterated a buy rating last month
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +115.80% per trade.
---